Connect with us

Cannabis News

Medical Marijuana Helps People Stop Using Opioids, Sleeping Aids And Other Prescription Drugs, Study Shows

Published

on

Using medical marijuana appears to help reduce the use of other medications, including opioids, sleep aids and antidepressants, according to a new study of more than 3,500 patients. They experience far fewer negative side effects after switching from prescription drugs to cannabis.

The survey results show that across all medication categories, patients were able to reduce their use of other prescription drugs by an average of 84.5 percent after starting to use medical cannabis.

More than half of the patients (58.9 percent) completely stopped using other prescription drugs.

The study, conducted and published by medical cannabis and telehealth company Bloomwell, conducted an online survey of 3,528 patients in Germany last month.

“Through the use of medical cannabis, patients were able to reduce their use of other prescription medications by an average of 84.5% across all categories.”

93.4 percent of patients taking sleeping pills were able to cut their use in half after starting medical marijuana, and 75.5 percent were able to get off the medication completely.

For methylphenidate, an ADHD drug sold under the name Ritalin, 77.3 percent of medical marijuana patients stopped completely.

61 percent of patients who were previously dependent on opioids were able to stop completely with the help of medical marijuana.

Stopping the use of prescription drugs led to a significant reduction in drug-related side effects, with 60.7 percent reporting no longer experiencing them.

“These patient reports demonstrate that in many cases, in addition to the treatment of the actual symptoms, one of the key reasons for an individual therapeutic trial with medical cannabis is the absence or reduction of medication-related side effects,” the study concluded.

“60.7% of patients reported no longer experiencing medication-related side effects from using medical cannabis.”

There were positive side effects, however, with 67.8 percent saying medical cannabis helped them concentrate better, 61.9 percent said it helped them foster more social relationships, and 53.9 percent experienced fewer sick days from work.

“The primary reason for prescribing medicinal cannabis, in addition to treating symptoms, is to reduce or avoid the side effects of other medications,” Julian Wichmann, Bloomwell’s founder and CEO, said in a press release. “For example, anyone who can completely stop opioids using medical cannabis has a good chance of going about their daily lives and working without side effects.”

“So we shouldn’t demand restrictions on access to medical cannabis, but rather make sure doctors are willing to do an individual therapeutic trial with medical cannabis, or at least recommend it and refer patients to their colleagues,” he said. “At the same time, our survey shows that we should finally discuss the great benefits of medical cannabis more openly, instead of only warning about the empirically unproven risks and discrediting the flower.”

This is not the first study to position medical cannabis as a safer alternative to opioids and other prescription drugs.

About One in three Americans who use CBD say they take it as an alternative or supplement to at least one medication—especially painful ones—according to a federally funded study published in February.

Also, a recent federally funded study, published by the American Medical Association (AMA), added further evidence Marijuana can be an effective substitute for opioids in the treatment of chronic pain.

Other studies published by the AMA have found legalizing marijuana for medical or recreational purposes “Significantly associated with reduced opioid use among patients diagnosed with cancer.”

A separate paper published in October also found that Legalizing medical marijuana “is associated with a significant reduction in opioid prescriptions.”

In August, however, Australian researchers published a study that shows this Marijuana can be an effective substitute for opioids in pain management treatment.

Another study published last year in the journal Drug and Alcohol Review found that daily drug users with chronic pain cannabis use was associated with greater likelihood of opioid cessation-Especially among men.

Other studies also found this legalizing medical cannabis appears to have significantly reduced payments to doctors from opioid manufacturers who specialize in pain, the authors found that “this reduction is a consequence of the availability of medical marijuana as a substitute” for prescription analgesics.

Other recent studies also showed a decline in fatal opioid overdoses in jurisdictions where marijuana was legalized for adults. That research found a ‘consistent negative relationship’ between legalization and fatal overdoses, effects more pronounced in states that legalized cannabis earlier in the opioid crisis. The authors estimated that legalizing recreational marijuana “is associated with a decrease of 3.5 deaths per 100,000 people.”

“Our findings suggest that expanding access to recreational marijuana could help combat the opioid epidemic,” the report said. “Prior studies overwhelmingly indicate that marijuana (especially for medical use) can reduce opioid prescriptions, and we see it successfully reducing overdose deaths as well.”

Another recently published report on prescription opioid use in Utah follows the state legalizing medical marijuana found that the availability of legal cannabis reduced opioid use among chronic pain patients and helped reduce prescription drug overdose deaths across the state. Overall, the study’s results indicated that “cannabis plays a significant role in pain management and reducing opioid use,” he said.

President Donald Trump said in December that marijuana can “make people feel a lot better.” and serves as a “substitute for addictive and potentially deadly opioid painkillers.” issued an executive order to federally regulate cannabis and promote access to CBD for therapeutic purposes. He clarified, however, that he personally has no interest in using marijuana himself.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Cannabis News

MMJDaily will be back August 10th

Published

on

By


Even the best growers need a dark cycle. MMJDaily is shutting down for the annual two-week summer break. There will be no newsletter in your inbox or new articles on the website for the next two weeks, but we will be back on August 10th. Thank you, as always, for following and supporting our work. Rest…

Continue Reading

Cannabis News

Adding Hemp To Dog Food Improves Digestive Health, New Study Shows

Published

on

By

A new study has found that adding hemp oil or a hemp seed byproduct to dog food can improve digestive health without negatively affecting the overall microbial system.

Research published in the journal Veterinary Sciences suggests that some types of hemp derivatives can be safely included as ingredients in dog food. However, the effects appear to depend in part on whether the cannabis is added as an oil or fiber supplement.

For the study, researchers at Kasetsart University in Thailand divided 24 mixed-breed dogs into three groups: one fed food with an 11 percent concentration of a high-fiber hemp seed byproduct, one received food containing 2 percent hemp seeds, and a third received a control diet without hemp.

The dogs were fed the diets for 90 days. The researchers compared the stool samples before the experiment and after 30 and 90 days. Genetic sequencing was used to track changes in gut bacterial composition and diversity.

Dogs fed hemp seed oil-infused food experienced a greater increase in microbial species richness.

“Hemp seeds modulate the canine microbiome without disrupting the ecological stability of the specific formulation, contributing to beneficial health effects in canine nutrition.”

The diet was also associated with increased levels of “beneficial” bacteria from the Lactobacillaceae family, and the fiber-rich hemp seed byproduct Actinobacteriota.

“Hemp seed derivatives altered the microbial composition by promoting beneficial bacteria that promoted gut health in dogs in a formulation-dependent manner,” the authors wrote, and the results “provide evidence for their inclusion as a functional ingredient in dog food.”

Despite the differences between the diets, 19 key bacterial collections were present throughout to analyze. And by day 90, the microbial composition also seemed to stabilize, indicating that the dietary supplements did not significantly disrupt the dogs’ intestinal systems.

Overall, the findings suggest that hemp seed ingredients can be safely incorporated into dog food while protecting gut health by promoting beneficial bacteria, the study authors said.

This is one of the latest studies on cannabis and its effects on dogs.


It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.


Learn more about our marijuana bill tracking and become a Patreon supporter to gain access

For example, a systematic review of the scientific literature determined that studies “consistently show” this CBD is a potential “anti-cancer agent” in various types of cancer—and this effect applies to both dogs and humans.

The National Animal Supplement Council (NASC) sponsored a study in 2024 said that CBD is “safe for long-term use” in dogs—This is a significant finding given the emerging research that cannabis can effectively treat anxiety and certain skin conditions in dogs.

Another 2024 case study found this Cannabis appears to be a “viable alternative” treatment option for dogs suffer from a common skin disease, especially if they suffer from the adverse side effects of conventional steroid therapies.

Meanwhile, previous research suggests that Giving dogs a dose of CBD can help reverse the ill effects of accidental THC consumptionaccording to a study by the authors titled “First report of treatment of THC toxicosis in dogs with administration of CBD.”

Another study published in 2024 found that Dogs receiving daily doses of CBD see “significant reductions” in stress and anxiety related to car trips.

Other studies have demonstrated the benefits of CBD, such as the frequency of seizures among dogs receiving the cannabinoid is reduced. Moreover, a study published in 2018 found this dogs with arthritis see improvements with CBD treatment.

As for other animals, it was discovered by the US Department of Agriculture (USDA) in 2013 Cows fed hempseed cake maintain very low concentrations of THC and CBD in their bodies, indicating that meat products from hemp-fed cows are safe for human consumption.

Another federally funded study published in 2022 found this Feeding hemp to cows reduces stress.

It has also been studied by researchers How CBD affects stress and pain in horses.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Become a patron on Patreon!

Continue Reading

Cannabis News

Ora Pharm affirms uninterrupted access to Helius products

Published

on

By

Ora Pharm has confirmed that New Zealand patients, prescribers and pharmacies continue to have uninterrupted access to Helius Therapeutics products following the successful acquisition of the business and its key assets, directly challenging the misinformation being circulated to patients and prescribers by cannabis importer MW Pharma Limited (trading as NUBU).

Industry monitoring was highlighted on Monday, July 20th, when Helius Therapeutics announced that NZ Grow Co. As he inaugurated Growers Day. The event demonstrated the full operational strength, advanced capabilities and integrated supply chain now fully operational under Ora Pharm’s leadership to support the growth of the NZ sector.

At the event, CEO Zoë Reece addressed concerns stemming from a July 9 industry bulletin distributed by NUBU, which stated that “Helius Therapeutics has ceased production and all products are now discontinued.”

© Ora Pharm

Ora Pharm said the statement was incorrect and had the potential to create unnecessary uncertainty in a highly regulated healthcare sector.

“Inaccurate information about the availability of medicines can cause unnecessary worry for patients, prescribers and pharmacies, interfere with treatment decisions and undermine confidence in the New Zealand cannabis industry.”

Ora Pharm completed the business and acquisition of key assets of Helius Therapeutics on June 18, 2026, resuming manufacturing, packaging and nationwide distribution the following day. All Helius brand formulated products and locally grown products remain approved and available for patient supply.

CEO Zoë Reece said the company’s focus is on ensuring continuity of care while strengthening New Zealand’s medicinal cannabis industry.

“The Helius facility gives New Zealand growers direct access to world-class pharmaceutical drying, extraction and manufacturing capabilities. Combined with NZ Grow Co., we are creating a secure and integrated pathway from cultivation to finished products and international markets. Our focus is on clinical continuity, quality assurance and confidence in patients and prescribing physicians every day.”

© Ora Pharm

The integration of the GMP-certified Auckland manufacturing facility with NZ Grow Co.’s cultivation network creates New Zealand’s largest medicinal cannabis supply chain. This unified network insulates domestic patients from volatile international import dependencies while providing independent local growers with a transparent, high-standard route to export markets.

Ora Pharm remains committed to working collaboratively across the sector to support patient access, strengthen confidence in the New Zealand cannabis industry and continue to invest in New Zealand’s pharmaceutical manufacturing capacity.

For more information:
Ora Pharm
(email protected)
www.orapharm.co.nz

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media